- Home
- SEVN vs EDIT Comparison
SEVN vs EDIT Comparison
Compare SEVN & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SEVN | EDIT |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 206.0M |
| IPO Year | 2008 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SEVN | EDIT |
|---|---|---|
| Price | $8.61 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $11.50 | $4.50 |
| AVG Volume (30 Days) | 95.7K | ★ 1.4M |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | $29,383,000.00 | ★ $31,937,000.00 |
| Revenue This Year | $18.03 | N/A |
| Revenue Next Year | $22.01 | N/A |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $8.30 | $0.91 |
| 52 Week High | $13.02 | $4.54 |
Technical Indicators
Market Signals| Indicator | SEVN | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 45.84 |
| Support Level | $8.59 | $1.66 |
| Resistance Level | $8.95 | $2.36 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 45.83 | 37.42 |
Price Performance
Historical ComparisonAbout SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.